Accedi a banche dati online | Convegnodetail
mail
Anteprima di stampa
 
 

4th Annual RAS Targeted Drug Development Summit

Evvnt Promotion / evvnt
-
26.09.2022 - 28.09.2022  Boston Marriott Burlington, One Burlington Mall Road, 01803 Burlington, Massachusetts, USA
Time: 8:30 AM - 6:00 PM
 
Temi della conferenza
For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring the RAS mutation.
Professional congress organizer (PCO)
Hanson Wade
 

Informazioni ed Iscrizioni:

https://go.evvnt.com/1209735-2?pid=4832
Ms. Erin Thomas
 
Categorie
Medicina General
Lingua
Inglese
Quote del Congresso
USD 2599.00 - USD 5398.00
I partecipanti attesi
1000
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."

Center of ExcellenceÖsterreichisches Rotes KreuzHilfswerk AustriaEuropean Health Forum GasteinCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioOÖ Gebietskrankenkasse, Referat für Wissenschaftskooperation AGEM - Arbeitsgemeinschaft Ethnologie und MedizinnewTree